Merck Stock Slips After Positive Diabetic Macular Edema Study Results

Merck's stock closed down 1.8% on September 3, 2026, at $148.1 after announcing topline results from its Phase 2b/3 study of an investigational therapy for diabetic macular edema.

The company announced that Remigromig met the primary endpoint in this pivotal study, demonstrating non-inferiority to ranibizumab for best-corrected visual acuity at week 52.

Remigromig's performance was evaluated in adults with diabetic macular edema in the BRUNELLO study. The results suggest that Remigromig could be a viable treatment option for patients with this condition.

The technical outlook for Merck remains bullish, with 78 of 113 analysts rating the company a buy. HSBC maintains a $172 price target with a buy rating.